Victor Hirsch
Hematology & Oncology · Abilene, TXNPI 1720089931
Payments from drug & device makers
Across 94 payments — averaging $15.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$385
- Johnson & Johnson$110
- Novartis$108
- AstraZeneca$79
- Genentech USA, Inc.$74
- Amgen$69
- plus $610 from 16 others
What the payments were for
- Food & beverage$1,30091%
- Education$1369%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 38 | $385 |
| Johnson & Johnson | 7 | $110 |
| Novartis | 6 | $108 |
| AstraZeneca | 5 | $79 |
| Genentech USA, Inc. | 4 | $74 |
| Amgen | 4 | $69 |
| Seagen Inc. | 1 | $65 |
| Eisai Inc. | 3 | $62 |
| Bristol Myers Squibb | 3 | $61 |
| Puma Biotechnology, Inc. | 3 | $57 |
| Bayer | 3 | $56 |
| Gilead | 2 | $53 |
| Mirati Therapeutics, Inc. | 2 | $53 |
| Merck | 3 | $48 |
| Sanofi | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| EUSA Pharma (US) LLC | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Verastem, Inc. | 1 | $11 |
How this compares
$1,435 in reported general payments places this provider in the 25th percentile of 838 hematology & oncology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 12 | $198,521 |
| ImbruvicaIbrutinib | 12 | $194,394 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $484 |
| Anastrozole | 15 | $169 |
| Levothyroxine Sodium | 13 | $94 |
| Furosemide | 27 | $30 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $15 | $198,52112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Abilene
- Elias JabbourHouston$264.1M
- Luhua WangHouston$79.6M
- Courtney DinardoHouston$74M
- Jorge Cortes-FrancoHouston$59.4M
- William WierdaHouston$58.7M
- Koji SasakiHouston$39.2M
- Kyriakos PapadopoulosSan Antonio$18.5M
- Loretta NastoupilHouston$18.3M
- Christopher FlowersHouston$17.2M
- Drew RascoSan Antonio$14.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.